June #82 : Classical Lit - by Cindra Feuer

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Kiss & Gel

Odd Boy Out

Pain Killer Pain

Gravest Show on Earth

Enemy at the Gate

How to Parent

On the High Wire

Party Politics

PACHA Gotcha

Waste Product

Three Wise Men

Poppy Culture

State of Race

Jail Tail

Ohio File

Oh! Calcutta!

School for Scandal

B Sting

Stat Splat

Beg To Differ

Oh, God!

Laughing Matters

Cable Ace

Bullox over Broadway

A Pair of Genes

Gene Machine


Fly by Night

All the News That's Fit to Zip...

Classical Lit

The Pill Chill

Mixed Signals

Tat's Two

Gender Bender


Who's Who

Big Sis

Clean Screen



Asimov As He Was


Tricks of the Trade

Cunning Linguist

Editor's Letter


Bloodless, Still Gutsy

Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

June 2002

Classical Lit

by Cindra Feuer

The latest experimental-treatment buzz is all about Merck's vaccine and the new outside-the-cell weapons called entry inhibitors and integrase inhibitors (see "Seattle Rattle," POZ, May 2002). But don't let these innovations distract you from the progress made in the classic classes of NNRTIs and protease inhibitors (PIs). Given resistance and side effects, the need for smarter, gentler versions of the 16 HAART drugs currently available could not be clearer. Luckily there are 98 promises in the pipeline, and some are even nearing the 2004 finish line: Two second-generation NNRTIs -- Tibotec-Virco's TMC 125 and Bristol-Myers Squibb's DPC 083 -- have been designed to disarm virus that has already developed resistance to older non-nukes. In the recently completed Phase II clinical trials, TMC 125 dramatically decreased viral loads in the NNRTI-resistant as well as in the NNRTI-naïve. Let's hope the current dose of 18 pills twice daily also dramatically decreases if and when TMC 125 hits shelves. DPC 083, in Phase II, is also ruthless in overcoming NNRTI-resistant virus.

Bristol-Myers Squibb's atazanavir (Zrivada) is the first once-daily PI. In studies of previously untreated HIVers, 48-week data showed that the drug didn't max out lipids (cholesterol and triglycerides) as do the first-generation PIs, leading to cardio side effects. Look for atazanavir to be up and at 'em as soon as late 2003. Boehringer Ingelheim's tipranavir is the first non-peptidic PI. It boasts an increased ability to bind to a drug-resistant virus more readily than to unmutated HIV. Phase II studies showed that tipranavir, with a little boost from fellow PI ritonavir (Norvir), picked up the slack by KO'ing viral loads even in those whose second PI regimen had failed.

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.